The Science of Certainty
Gubra enables you to progress your preclinical pharmacology development for metabolic disorders with more certainty than any other research partner. We offer highly specialized services within five main disease areas.
Gubra response measures to corona virus/covid-19
During the global coronavirus outbreak, Gubra’s key priority is to help the authorities in limiting spread of disease and protect our employees and their families, while at the same time safeguard a continued supply of research services to our partners and customers. The situation is continually evolving, but currently we are not experiencing any constraints and our study activities are running according to plans.
We have worked out detailed contingency plans for situations like this including inventory and staffing policy/plans that serves to maintain a continuity in deliveries.
3D imaging of neurons
Light-sheet fluorescence microscopy allows for 3D imaging, mapping and quantification of neurons at single cell resolution throughout the entire, intact mouse brain.
In animal models of Parkinson Disease (PD) estimation of dopaminergic neuron numbers and projections are imperative for model phenotyping and assessment of drug treatment effects.
– a customized service
With a strong academic background in neuroscience and neurostereology we have conducted several preclinical studies of neurodegenerative diseases, including Parkinson and Alzheimers Disease.
Do you want to be part of a great team aiming high? Join us.
Our ambition is that Gubra is a place where talented people are empowered to put their competencies and passion into play every day. We work as a team to make a difference for people with serious metabolic diseases.